John Oyler, BeiGene CEO (Paul Yeung/Bloomberg via Getty Images)
BeiGene notches win for PD-1 drug in stomach cancers. When will partner Novartis submit for approval?
BeiGene announced Thursday morning that its immune checkpoint inhibitor helped patients with certain stomach cancers live longer than chemotherapy alone. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.